Barclays Upgrades CVS Health to Overweight, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Andrew Mok has upgraded CVS Health from Equal-Weight to Overweight and increased the price target from $63 to $82.
October 10, 2024 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Andrew Mok upgraded CVS Health to Overweight and raised the price target to $82, indicating a positive outlook for the stock.
The upgrade from Equal-Weight to Overweight by Barclays suggests increased confidence in CVS Health's performance. The raised price target from $63 to $82 indicates expectations of significant upside potential, likely leading to positive investor sentiment and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100